Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab (MRA) plus methotrexate versus placebo plus methotrexate in anti-TNF inadequate responder rheumatoid arthritis
2005-000884-25Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Tocilizumab (MRA) plus methotrexate with Placebo plus methotrexate (2 arms). Primary endpoint: ACR20 response at week 24. Started Apr 2005; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-000884-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000884-25.